View Older Stories View More Recent Stories

Jan 22, 2020 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2020 First Quarter Results
Jan 6, 2020 07:30AM Arrowhead Pharmaceuticals Appoints James Hassard as Chief Commercial Officer
Dec 20, 2019 07:33AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports First Patient Dosing in AROAAT2002 Open Label Phase 2 Study of ARO-AAT
Dec 20, 2019 07:30AM Arrowhead Pharmaceuticals Doses First Patient in AROAAT2002 Open Label Phase 2 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Dec 16, 2019 04:15PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Dec 16, 2019 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports Filing for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD
Dec 16, 2019 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-HSD for Treatment of Alcohol and Nonalcohol Related Liver Disease
Dec 13, 2019 07:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Announces Marianne De Backer to Board
Dec 13, 2019 07:30AM Arrowhead Pharmaceuticals Appoints Marianne De Backer to Board of Directors
Dec 11, 2019 07:31AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports Filing of IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Dec 11, 2019 07:30AM Arrowhead Pharmaceuticals Files IND for Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Nov 26, 2019 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming December 2019 Conferences
Nov 25, 2019 04:00PM Arrowhead Pharmaceuticals Reports Fiscal Year 2019 Results
Nov 18, 2019 09:32AM Arrowhead Presents New Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at AHA Scientific Sessions 2019
Nov 15, 2019 07:34AM Arrowhead (ARWR) announces Bruce Given, M.D., COO and head of R&D, plans to retire
Nov 15, 2019 07:30AM Arrowhead Pharmaceuticals Announces Planned Management Transition
Nov 11, 2019 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Year End Results
Nov 8, 2019 08:06AM Arrowhead Pharmaceuticals Corp (ARWR), Janssen Pharmaceuticals, Inc. Announce Phase 2 Clinical Data for Investigational Hepatitis B Regimens
Nov 8, 2019 08:00AM Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data for Investigational Hepatitis B Regimens at The Liver Meeting® 2019
Oct 31, 2019 12:18PM Arrowhead Pharmaceuticals Corp (ARWR) Presents Preclinical Data on ARO-ENaC at NACFC
Oct 31, 2019 12:15PM Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ENaC at the North American Cystic Fibrosis Conference
Oct 18, 2019 07:30AM Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of RNAi Therapeutics
Sep 30, 2019 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming October 2019 Conferences
Sep 20, 2019 04:00PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Sep 16, 2019 06:20AM Arrowhead Pharmaceuticals (ARWR) Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
Sep 16, 2019 03:00AM Arrowhead Pharmaceuticals Presents Initial Top-Line Clinical Data and Preclinical Data on RNAi Candidates ARO-APOC3 and ARO-ANG3
Aug 30, 2019 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming September 2019 Conferences
Aug 28, 2019 07:41AM Arrowhead Pharmaceuticals Corp (ARWR) Collaborator Janssen Commences REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection
Aug 28, 2019 07:30AM Arrowhead Collaborator Janssen Begins REEF-1 Phase 2b Combination Study in Patients with Chronic Hepatitis B Infection
Aug 8, 2019 07:40AM Arrowhead Pharmaceuticals Corp (ARWR) Reports First Patient Dosing in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Aug 8, 2019 07:30AM Arrowhead Pharmaceuticals Doses First Patient in SEQUOIA Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Aug 5, 2019 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2019 Third Quarter Results
Jul 24, 2019 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Third Quarter Results
Jul 16, 2019 04:10PM Arrowhead Pharmaceuticals Corp (ARWR) Granted Orphan Drug Designation for ARO-ANG3
Jul 16, 2019 04:00PM Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-ANG3
Jul 8, 2019 07:30AM Arrowhead Pharmaceuticals to Participate in Roth RNA Revolution Conference
Jun 27, 2019 07:31AM Arrowhead Pharmaceuticals Corp (ARWR) Granted Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease
Jun 27, 2019 07:30AM Arrowhead Pharmaceuticals Receives Fast Track Designation for ARO-AAT for Treatment of Alpha-1 Liver Disease
Jun 21, 2019 06:45PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Jun 21, 2019 07:31AM Arrowhead Pharmaceuticals (ARWR) Confirms it Received Orphan Drug Designation for ARO-APOC3
Jun 21, 2019 07:30AM Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3
May 31, 2019 04:00PM Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences
May 8, 2019 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2019 Second Quarter Results
May 2, 2019 07:30AM Arrowhead Pharmaceuticals to Present at Upcoming May 2019 Conferences
Apr 24, 2019 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2019 Second Quarter Results
Apr 24, 2019 07:39AM Arrowhead Pharmaceuticals Corp (ARWR) Commences Triple Combination Cohort in Chronic HBV Patients; Reports $25M Milestone Payment from Janssen
Apr 24, 2019 07:30AM Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from Janssen
Apr 15, 2019 07:36AM Arrowhead Pharma (ARWR) Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Apr 15, 2019 07:30AM Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
Apr 12, 2019 12:46PM Arrowhead (ARWR) Presents Clinical Data on JNJ-3989 (ARO-HBV) at EASL
View More Recent Stories View Older Stories